{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:06:42Z","timestamp":1789852002143,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.arbres.2026.08.006","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:47:20Z","timestamp":1789764440000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Randomized, Open-Label, Parallel Group Study of Alpha-1 Antitrypsin Therapy in Hospitalized Patients With COVID-19"],"prefix":"10.1016","author":[{"given":"Luis","family":"Puente Maestu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Calle Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mart\u00edn Bote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"L\u00e1zaro-Asegurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00ednez-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Mondou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2026.08.006_bib0210","series-title":"Number of COVID-19 deaths reported to WHO (cumulative total)","author":"World Health Organization","year":"2024"},{"issue":"18","key":"10.1016\/j.arbres.2026.08.006_bib0215","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.arbres.2026.08.006_bib0220","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","article-title":"Severe covid-19","volume":"383","author":"Berlin","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.arbres.2026.08.006_bib0225","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1164\/rccm.202005-1583OC","article-title":"Characterization of the inflammatory response to severe COVID-19 illness","volume":"202","author":"McElvaney","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.arbres.2026.08.006_bib0230","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.08.006_bib0235","doi-asserted-by":"crossref","first-page":"802228","DOI":"10.3389\/fphar.2022.802228","article-title":"Increased circulating cytokines have a role in COVID-19 severity and death with a more pronounced effect in males: a systematic review and meta-analysis","volume":"13","author":"Hu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.arbres.2026.08.006_bib0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1165\/rcmb.2002-0258OC","article-title":"Inhibition of proteinase 3 by [alpha]1-antitrypsin in vitro predicts very fast inhibition in vivo","volume":"29","author":"Duranton","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"217","key":"10.1016\/j.arbres.2026.08.006_bib0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007116","article-title":"The circulating proteinase inhibitor \u03b1-1 antitrypsin regulates neutrophil degranulation and autoimmunity","volume":"6","author":"Bergin","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.arbres.2026.08.006_bib0250","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1172\/JCI41196","article-title":"\u03b1-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8","volume":"120","author":"Bergin","year":"2010","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.arbres.2026.08.006_bib0255","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000445692","article-title":"Alpha-1 antitrypsin deficiency today: new insights in the immunological pathways","volume":"91","author":"Baraldo","year":"2016","journal-title":"Respiration"},{"issue":"12","key":"10.1016\/j.arbres.2026.08.006_bib0260","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1074\/jbc.M607976200","article-title":"Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating Camp","volume":"282","author":"Janciauskiene","year":"2007","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.arbres.2026.08.006_bib0265","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1189\/jlb.0208145","article-title":"Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood","volume":"85","author":"Pott","year":"2009","journal-title":"J Leukoc Biol"},{"issue":"5","key":"10.1016\/j.arbres.2026.08.006_bib0270","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.arbres.2026.08.006_bib0275","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.arbres.2026.08.006_bib0280","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2020040426","article-title":"Clinicopathological features and outcomes of acute kidney injury in critically ill COVID-19 with prolonged disease course: a retrospective cohort","volume":"31","author":"Xia","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.arbres.2026.08.006_bib0285","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.arbres.2026.08.006_bib0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.20411\/pai.v6i1.408","article-title":"Alpha 1 antitrypsin is an inhibitor of the SARS-CoV-2-priming protease TMPRSS2","volume":"6","author":"Azouz","year":"2021","journal-title":"Pathog Immun"},{"issue":"1","key":"10.1016\/j.arbres.2026.08.006_bib0295","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1038\/s41598-022-10890-w","article-title":"Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19","volume":"12","author":"Bai","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.arbres.2026.08.006_bib0300","doi-asserted-by":"crossref","first-page":"e2157","DOI":"10.1002\/rmv.2157","article-title":"Alpha-1-antitrypsin: a possible host protective factor against Covid-19","volume":"31","author":"de Loyola","year":"2021","journal-title":"Rev Med Virol"},{"issue":"12","key":"10.1016\/j.arbres.2026.08.006_bib0305","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/23744235.2022.2111464","article-title":"Lower serum alpha 1 antitrypsin levels in patients with severe COVID-19 compared with patients hospitalized due to non-COVID-19 pneumonia","volume":"54","author":"Pertzov","year":"2022","journal-title":"Infect Dis (Lond)"},{"issue":"2","key":"10.1016\/j.arbres.2026.08.006_bib0310","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/biomedicines11020516","article-title":"Severe COVID-19 illness and alpha1-antitrypsin deficiency: COVID-AATD study","volume":"11","author":"Rodriguez Hermosa","year":"2023","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.arbres.2026.08.006_bib0315","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.arbres.2022.07.002","volume":"58","author":"Parr","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2026.08.006_bib0320","doi-asserted-by":"crossref","first-page":"106387","DOI":"10.1016\/j.rmed.2021.106387","article-title":"Alpha-1 antitrypsin deficiency severity and the risk of COVID-19: a Portuguese cohort","volume":"181","author":"Faria","year":"2021","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.arbres.2026.08.006_bib0325","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/pedi.13162","article-title":"Human plasma-derived alpha(1)-proteinase inhibitor in patients with new-onset type 1 diabetes mellitus: a randomized, placebo-controlled proof-of-concept study","volume":"22","author":"Lagarde","year":"2021","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.arbres.2026.08.006_bib0330","unstructured":"Smith GB. National Early Warning Score (NEWS) 2014. https:\/\/www.mdcalc.com\/calc\/1873\/national-early-warning-score-news#when-to-use [accessed 29.4.26]."},{"key":"10.1016\/j.arbres.2026.08.006_bib0335","unstructured":"Adaptive COVID-19 Treatment Trial (ACTT) 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04280705 [accessed 29.4.26]."},{"issue":"3","key":"10.1016\/j.arbres.2026.08.006_bib0340","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.2067","article-title":"Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS","volume":"210","author":"He","year":"2006","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.arbres.2026.08.006_bib0345","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/JVI.02576-13","article-title":"Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival","volume":"88","author":"DeDiego","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.arbres.2026.08.006_bib0350","doi-asserted-by":"crossref","first-page":"832394","DOI":"10.3389\/fimmu.2022.832394","article-title":"The role of cytokines and chemokines in severe acute respiratory syndrome coronavirus 2 infections","volume":"13","author":"Hsu","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.arbres.2026.08.006_bib0355","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.medj.2022.03.001","article-title":"A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for acute respiratory distress syndrome secondary to COVID-19","volume":"3","author":"McElvaney","year":"2022","journal-title":"Med"},{"issue":"17","key":"10.1016\/j.arbres.2026.08.006_bib0360","doi-asserted-by":"crossref","first-page":"13533","DOI":"10.3390\/ijms241713533","article-title":"Could the oxidation of alpha1-antitrypsin prevent the binding of human neutrophil elastase in COVID-19 patients?","volume":"24","author":"D\u2019Amato","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arbres.2026.08.006_bib0365","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/s41598-026-35016-4","article-title":"COVID-19 outcomes in individuals with severe alpha-1 antitrypsin deficiency in Sweden","volume":"16","author":"Zaigham","year":"2026","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.arbres.2026.08.006_bib0370","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2013 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.arbres.2026.08.006_bib0375","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.jiph.2023.07.006","article-title":"COVID-19 fatality rates in hospitalized patients: a new systematic review and meta-analysis","volume":"16","author":"Baptista","year":"2023","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.arbres.2026.08.006_bib0380","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.annepidem.2021.02.012","article-title":"COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis","volume":"57","author":"Macedo","year":"2021","journal-title":"Ann Epidemiol"},{"issue":"9","key":"10.1016\/j.arbres.2026.08.006_bib0385","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1377\/hlthaff.2021.00619","article-title":"Vaccinations against COVID-19 may have averted up to 140,000 deaths in the United States","volume":"40","author":"Gupta","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"10287","key":"10.1016\/j.arbres.2026.08.006_bib0390","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.arbres.2026.08.006_bib0395","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.arbres.2026.08.006_bib0400","doi-asserted-by":"crossref","DOI":"10.1017\/ash.2021.195","article-title":"The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis","volume":"1","author":"Marra","year":"2021","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"10.1016\/j.arbres.2026.08.006_bib0405","doi-asserted-by":"crossref","first-page":"1397040","DOI":"10.3389\/fimmu.2024.1397040","article-title":"Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity","volume":"15","author":"Razonable","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.08.006_bib0410","doi-asserted-by":"crossref","first-page":"116643","DOI":"10.1016\/j.diagmicrobio.2024.116643","article-title":"The development of therapeutics and vaccines against COVID-19","volume":"111","author":"Zhao","year":"2024","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626003133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626003133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:51:48Z","timestamp":1789851108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289626003133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["S0300289626003133"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2026.08.006","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Open-Label, Parallel Group Study of Alpha-1 Antitrypsin Therapy in Hospitalized Patients With COVID-19","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2026.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}